313 related articles for article (PubMed ID: 32183301)
21. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
[TBL] [Abstract][Full Text] [Related]
22. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
23. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
Yoon JH; Ahn SG; Lee BH; Jung SH; Oh SH
Biochem Pharmacol; 2012 Mar; 83(6):747-57. PubMed ID: 22226932
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
25. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Kyle S; Thomas HD; Mitchell J; Curtin NJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
[TBL] [Abstract][Full Text] [Related]
26. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
27. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Ivy SP; Kunos CA; Arnaldez FI; Kohn EC
Expert Opin Investig Drugs; 2019 Sep; 28(9):771-785. PubMed ID: 31449760
[No Abstract] [Full Text] [Related]
28. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
29. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers.
Alhusaini A; Cannon A; Maher SG; Reynolds JV; Lynam-Lennon N
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440228
[TBL] [Abstract][Full Text] [Related]
31. Modulation of hypersensitivity to oxidative DNA damage in ATM defective cells induced by potassium bromate by inhibition of the Poly (ADP-ribose) polymerase (PARP).
Mosesso P; Piane M; Pepe G; Cinelli S; Chessa L
Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt A):117-123. PubMed ID: 30389154
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
33. Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives.
Zimmer K; Kocher F; Puccini A; Seeber A
Front Oncol; 2021; 11():662055. PubMed ID: 34707985
[TBL] [Abstract][Full Text] [Related]
34. Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by
D'Ambrosio C; Erriquez J; Capellero S; Cignetto S; Alvaro M; Ciamporcero E; Di Renzo MF; Perera T; Valabrega G; Olivero M
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628590
[TBL] [Abstract][Full Text] [Related]
35. Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition.
Aguilar-Quesada R; Muñoz-Gámez JA; Martín-Oliva D; Peralta A; Valenzuela MT; Matínez-Romero R; Quiles-Pérez R; Menissier-de Murcia J; de Murcia G; Ruiz de Almodóvar M; Oliver FJ
BMC Mol Biol; 2007 Apr; 8():29. PubMed ID: 17459151
[TBL] [Abstract][Full Text] [Related]
36. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
37. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
38.
Schmitt A; Knittel G; Welcker D; Yang TP; George J; Nowak M; Leeser U; Büttner R; Perner S; Peifer M; Reinhardt HC
Cancer Res; 2017 Jun; 77(11):3040-3056. PubMed ID: 28363999
[TBL] [Abstract][Full Text] [Related]
39. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
40. Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells.
Hou Z; Cui Y; Xing H; Mu X
Oncol Lett; 2018 Feb; 15(2):1943-1948. PubMed ID: 29434894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
